CymaBay Therapeutics, Inc. (CBAY) Is At $12.38 Formed Wedge; 6 Analysts Bullish accesso Technology Group plc (LON:ACSO)

accesso Technology Group plc (LON:ACSO) Logo

Among 6 analysts covering Accesso Technology Group (LON:ACSO), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Accesso Technology Group had 51 analyst reports since July 30, 2015 according to SRatingsIntel. The company was maintained on Tuesday, May 23 by Numis Securities. The company was maintained on Thursday, February 4 by Numis Securities. The stock of accesso Technology Group plc (LON:ACSO) has “Add” rating given on Monday, July 17 by Numis Securities. The firm earned “Add” rating on Wednesday, March 21 by Numis Securities. On Thursday, March 3 the stock rating was maintained by Peel Hunt with “Buy”. The stock of accesso Technology Group plc (LON:ACSO) earned “Buy” rating by Peel Hunt on Thursday, April 28. As per Thursday, November 10, the company rating was maintained by Peel Hunt. The firm earned “Add” rating on Thursday, September 14 by Numis Securities. Peel Hunt maintained accesso Technology Group plc (LON:ACSO) rating on Thursday, August 25. Peel Hunt has “Buy” rating and GBX 2100 target. Peel Hunt maintained it with “Buy” rating and GBX 1280 target in Thursday, March 17 report. See accesso Technology Group plc (LON:ACSO) latest ratings:

01/06/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 3100.00 Maintain
22/05/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 3100.00 Maintain
03/05/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 3100.00 Maintain
25/04/2018 Broker: Peel Hunt Rating: Buy New Target: GBX 3100.00 Maintain
04/04/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 3100.00 Maintain
26/03/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 3100.00 New Target: GBX 3100.00 Maintain
23/03/2018 Broker: Berenberg Rating: Buy Old Target: GBX 2700.00 New Target: GBX 3000.00 Maintain
21/03/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 3100.00 New Target: GBX 3100.00 Maintain
21/03/2018 Broker: Numis Securities Rating: Add Old Target: GBX 2560.00 New Target: GBX 2560.00 Maintain
15/03/2018 Broker: Peel Hunt Rating: Buy New Target: GBX 3100.00 Initiates Starts

CymaBay Therapeutics, Inc. (CBAY) formed wedge down with $12.01 target or 3.00% below today’s $12.38 share price. CymaBay Therapeutics, Inc. (CBAY) has $727.56 million valuation. The stock decreased 3.96% or $0.51 during the last trading session, reaching $12.38. About 583,949 shares traded. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has risen 171.12% since June 12, 2017 and is uptrending. It has outperformed by 158.55% the S&P500. Some Historical CBAY News: ; 11/04/2018 – CBAY:SELADELPAR SHOWED ANTI-INFLAMMATORY ACTIVITY THRU 26 WEEKS; 11/04/2018 – CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primar; 15/05/2018 – Vivo Capital Buys New 1.4% Position in Cymabay Therapeutics; 12/04/2018 – Companies that Stand to Benefit from the Biotech Market Bottoming; 11/04/2018 – CYMABAY THERAPEUTICS INC – RESULTS FROM PHASE 2 OF SELADELPAR STUDY REAFFIRM PLANS FOR ADVANCING TO PHASE 3 IN SECOND HALF OF 2018; 08/05/2018 – CymaBay Therapeutics 1Q Loss/Shr 32c; 15/05/2018 – Deerfield Management Buys 2.1% Position in Cymabay Therapeutics; 28/03/2018 – #EASL2018 late breakers still embargoed for official press program $CBAY PPARδ Ph2 PBC $NVS FXR Ph2 PBC @NGMBio FGF19 Ph2 PSC $ALNY Givosiran in AIP; 20/04/2018 – Report: Developing Opportunities within CymaBay Therapeutics, IAC/InterActiveCorp, Axcelis Technologies, La Quinta, Hornbeck Of; 08/05/2018 – CYMABAY THERAPEUTICS INC – EXISTING CASH IS EXPECTED TO FUND CYMABAY’S CURRENT OPERATING PLAN INTO 2021

Analysts await CymaBay Therapeutics, Inc. (NASDAQ:CBAY) to report earnings on August, 9. They expect $-0.24 earnings per share, up 22.58% or $0.07 from last year’s $-0.31 per share. After $-0.32 actual earnings per share reported by CymaBay Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -25.00% EPS growth.

Among 8 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc has $27.0 highest and $2.25 lowest target. $19.43’s average target is 56.95% above currents $12.38 stock price. Cymabay Therapeutics Inc had 31 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has “Buy” rating given on Monday, January 30 by H.C. Wainwright. The stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) earned “Neutral” rating by H.C. Wainwright on Wednesday, January 4. The stock has “Neutral” rating by H.C. Wainwright on Wednesday, June 1. As per Monday, April 16, the company rating was maintained by Roth Capital. The rating was maintained by Piper Jaffray with “Buy” on Wednesday, January 31. The firm earned “Buy” rating on Friday, July 1 by Roth Capital. Piper Jaffray maintained the stock with “Buy” rating in Monday, July 17 report. The firm has “Buy” rating by Roth Capital given on Thursday, January 25. Piper Jaffray maintained CymaBay Therapeutics, Inc. (NASDAQ:CBAY) rating on Tuesday, July 25. Piper Jaffray has “Buy” rating and $1200 target. On Tuesday, July 21 the stock rating was initiated by Piper Jaffray with “Overweight”.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Ratings Chart